

Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation

Nielsen, Peter Brønnum; Skjøth, Flemming; Rasmussen, Lars Hvilsted; Larsen, Torben Bjerregaard; Lip, Gregory Y.h.

DOI:

[10.1016/j.cjca.2015.01.034](https://doi.org/10.1016/j.cjca.2015.01.034)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Nielsen, PB, Skjøth, F, Rasmussen, LH, Larsen, TB & Lip, GYH 2015, 'Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation: a focus on vascular disease, females and simple practical application', *Canadian Journal of Cardiology*. <https://doi.org/10.1016/j.cjca.2015.01.034>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

NOTICE: this is the author's version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB, Lip GYH, Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation: A focus on vascular disease, females and simple practical application, *Canadian Journal of Cardiology* (2015), doi: 10.1016/j.cjca.2015.01.034.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript



Using the CHA₂DS₂-VASc score for stroke prevention in atrial fibrillation: A focus on vascular disease, females and simple practical application

Peter Brønnum Nielsen, PhD, Flemming Skjøth, PhD, Lars Hvilsted Rasmussen, MD PhD, Torben Bjerregaard Larsen, MD PhD, Gregory Y.H. Lip, MD

PII: S0828-282X(15)00081-1

DOI: [10.1016/j.cjca.2015.01.034](https://doi.org/10.1016/j.cjca.2015.01.034)

Reference: CJCA 1567

To appear in: *Canadian Journal of Cardiology*

Received Date: 8 December 2014

Revised Date: 27 January 2015

Accepted Date: 27 January 2015

Please cite this article as: Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB, Lip GYH, Using the CHA₂DS₂-VASc score for stroke prevention in atrial fibrillation: A focus on vascular disease, females and simple practical application, *Canadian Journal of Cardiology* (2015), doi: 10.1016/j.cjca.2015.01.034.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Letter to the Editor

Using the CHA₂DS₂-VASc score for stroke prevention in atrial fibrillation: A focus on vascular disease, females and simple practical application

Peter Brønnum Nielsen ¹	PhD
Flemming Skjøth ^{1,2}	PhD
Lars Hvilsted Rasmussen ^{1,2}	MD PhD
Torben Bjerregaard Larsen ^{1,2}	MD PhD
Gregory Y.H. Lip ^{1,3}	MD

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

² Department of Cardiology, Aalborg AF Study Group, Aalborg University Hospital, Denmark

³ University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

Correspondence to:

Prof Gregory YH Lip

Telephone: +44 121 507 5080; Fax: +44 121 507 5097; g.y.h.lip@bham.ac.uk

We recently provided evidence that using the new risk stratification algorithm approach from the Canadian Cardiovascular Society (CCS) Guidelines could leave patients with a high 1-year stroke rate (4.86 per 100 person-years)¹; hence, patients with such high stroke rates are not ‘low risk’, as acknowledged by Cairns et al. in their accompanying Editorial².

In the 2014 focused guidelines update, the CCS recommends use of the CHADS₂ schema referring to the original Gage et al publication³ (and thus implying use of a similar definition). Thus, patients with some risk factors already included within the CHA₂DS₂-VASc score would not have been included in the 2014 CCS guidelines. Indeed, it is very important to strictly define the precise criteria for providing points related to each component in risk stratification scoring systems, and we welcome a clarifying update from the CCS committee on this matter.

Notwithstanding this inconsistency/misinterpretation on definitions, Cairn et al. raises the concern that previous publications using the Danish nationwide registries showed different event rates relative to those we presented. However, the devil is in the detail. Different populations and inclusion criteria, study settings, definitions on outcomes and time frames may account for the variation in event rates seen in various studies (see Online Supplement for full details).

In an attempt to specify and fully describe our event rates challenged by Cairns et al., we are pleased to provide a stratified analysis of 987 patients with prior vascular disease. We defined the ‘VASc’ component as follows: prior myocardial infarction, prior peripheral artery disease, or aortic plaque, as we have done previously⁴. It is evident that all subgroups of prior vascular diseases carry a high one-year thromboembolic event rate, see Table 1. Contrasting low risk CHA₂DS₂-VASc (that is, score 0 (male) or 1 (female)) as a reference population vs those with ≥ 1 additional stroke risk factors (ie. CHA₂DS₂-VASc score =1 (male) or =2 (females)) to express the hazard attributable to vascular disease resulted in a crude HR of 2.7 (95%CI 1.7-4.2).

To investigate the subgroup of AF patients with a CHADS₂=0 and concomitant MI, we excluded those with prior peripheral artery disease and aortic plaque. Contrasting CHA₂DS₂-VASc=0 (male) or 1 (female) as reference population vs CHA₂DS₂-VASc score =1 (male) or =2 (females) resulted in a crude HR of 2.2 (95%CI 1.2-3.8) and 1.6 (95%CI 1.0-2.4), for one and five years follow-up, respectively. Thus, there is still a relative risk increase in ischemic stroke/SE/TIA in the AF group with prior MI.

Although long follow-up times (i.e. 10 or 12 years) may provide interesting insights into very long-term outcomes in AF patients, caution is warranted as baseline assumptions (on comorbidity and medication use) can be violated

To conclude, we could perhaps suggest a very simplified risk stratification and thromboprophylaxis algorithm based on the approach recommended by the ESC and NICE guidelines (see Online Figure S1). By assessing the CHA₂DS₂-VASc score it is possible to identify the truly low risk patients (0 (male) or 1 (female)), who do not need any antithrombotic therapy.

REFERENCES

1. Lip GYH, Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB. Atrial fibrillation patients categorised as “not for anticoagulation” with the 2014 Canadian Cardiovascular Society algorithm are not “low risk.” *Can. J. Cardiol.* 2014. doi:10.1016/j.cjca.2014.10.018.
2. Cairns JA, Healey J, Macle L, Mitchell B, Verma A. The New CCS Algorithm for Antithrombotic Therapy of Atrial Fibrillation is Appropriately Based on Current Epidemiologic Data. *Can. J. Cardiol.* 2014. doi:10.1016/j.cjca.2014.11.021.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;285(22):2864-70.
4. Lip GYH, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide co. *Chest* 2014;146(5):1337-46. doi:10.1378/chest.14-0533.

Table 1: Event rates (per 100 person-years) of ischemic stroke/SE/TIA in 980 AF patients (CHADS₂=0) with prior vascular disease stratified according to type for 1 and 5 years of follow-up*.

Type of vascular disease	Number of patients	1 year of follow-up		5 years of follow-up	
		Number of events /person-time	Event rate (95% CI)	Number of events /person-time	Event rate (95% CI)
MI	651	12/490	2.5 (1.4-4.3)	23/1,783	1.3 (0.9-1.9)
Peripheral artery disease	294	6/201	3.0 (1.3-6.7)	13/669	1.9 (1.1-3.4)
Both MI and peripheral artery disease	35	3/20	15.0 (4.8-46.4)	5/57	8.7 (3.6-21.0)

*Groups comprising ≤ 5 patients (e.g. aortic plaque and MI) have been omitted from the table (n=7 patients)

Online Supplement**Using the CHA₂DS₂-VASc score for stroke prevention in atrial fibrillation: A focus on vascular disease, females and simple practical application**

Peter Brønnum Nielsen ¹	PhD
Flemming Skjøth ^{1,2}	PhD
Lars Hvilsted Rasmussen ^{1,2}	MD PhD
Torben Bjerregaard Larsen ^{1,2}	MD PhD
Gregory Y.H. Lip ^{1,3}	MD

¹Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

² Department of Cardiology, Aalborg AF Study Group, Aalborg University Hospital, Denmark

³ University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

Correspondence to:

Prof Gregory YH Lip

Telephone: +44 121 507 5080; Fax: +44 121 507 5097; g.y.h.lip@bham.ac.uk

We recently provided the evidence that using the new risk stratification algorithm approach from the Canadian Cardiovascular Society (CCS) Guidelines could leave patients with a high 1-year stroke rate (4.86 per 100 person-years)¹; hence, patients with such high stroke rates are not ‘low risk’, as acknowledged by Cairns et al. in their accompanying Editorial².

In the 2012 CCS guidelines (as in the 2010) it was recommended to use the CHADS₂ scoring system for risk stratification³; however, the components were defined similarly to those of the CHA₂DS₂-VASc score. The ‘VASc’ component was in combination with female sex triggering a recommendation for anticoagulant treatment, but not vascular disease (nor female sex) alone. In the 2014 focused update, the CCS recommends use of the CHADS₂ schema referring to the original Gage et al publication⁴ (and thus implying use of a similar definition). Thus, patients with some risk factors already included within the CHA₂DS₂-VASc score would not have been included in the 2014 CCS guidelines. Indeed, it is very important to strictly define the precise criteria for providing points related to each component in risk stratification scoring systems, and we welcome a clarifying update from the CCS committee on this matter.

Notwithstanding this inconsistency/misinterpretation on definitions, we would like to specifically provide the evidence for a high stroke rate of 4.85 per 100 person-years in AF patients with vascular disease as a single risk factor. This corresponds to CHA₂DS₂-VASc=1 for males and a CHA₂DS₂-VASc=2 for females, where our paper reported rates of 4.53 and 5.69, respectively. We defined the ‘VASc’ component as follows: prior myocardial infarction, prior peripheral artery disease, or aortic plaque, as we have done previously⁵⁻⁸.

Cairn et al. raises the concern that previous publications using the Danish nationwide registries showed different event rates relative to those we presented. However, the devil is in the detail. The paper by Olesen et al.⁹ used a combined primary endpoint of ischemic stroke (ICD10: I63; I64),

pulmonary embolism (PE) (ICD10: I26) and systemic embolism (SE) (ICD10: I74) or death from either of these events (using the Danish Register of Cause of Death¹⁰) and had a different time frame, over the period of 1997 to 2006. Different populations and inclusion criteria, study settings, definitions on outcomes and time frames may account for the variation in event rates seen in various studies. A recent systematic review shows the accentuated stroke and thromboembolism risk where AF is associated with atherosclerotic vascular disease¹¹.

In a different report, also by Olesen et al.¹², AF patients with prior vascular disease were studied. In this study peripheral artery disease was somewhat more strictly defined (i.e. leaving out atherosclerosis of the aorta (ICD10: I700)). Cairns et al. notes that the event rates, reported in a supplementary analysis, for vascular disease were 1.07 % at one year (total of 5 events) and 1.61% at 12 years of follow-up (total of 42 events) for patients with a CHA₂DS₂-VASc =1. However, analysing the main results provided in this publication reveals that the thromboembolic event rate of 2.31% at one year for patients with a CHADS₂=0 was primarily affected by patients with peripheral artery disease (5.71% and 2.57% for patients with both peripheral artery disease and MI), while patients with prior MI (and no peripheral artery disease) displayed a thromboembolic event rate of 1.79%. The supplementary analysis of patients with a CHA₂DS₂-VASc=1 (referred to by Cairns et al.) included zero events in this subgroup of patients with prior peripheral artery disease; thus the event rate of 1.07% for one year was based solely on patients with prior MI.

Rasmussen et al.¹³ also studied the impact of vascular disease in predicting of stroke and death in an inception cohort of AF patients. After adjustments for risk factors within the CHADS₂ score, the adjusted hazard ratio (HR) at one year follow-up for the primary endpoint was 2.51 (95% confidence interval [CI] 1.91-3.29) contrasting AF patients with or without (latter being the reference population) prior vascular disease.

In an attempt to specify and fully describe our event rates challenged by Cairns et al., we are pleased to provide a stratified analysis of 987 patients with prior vascular disease (as defined in our CCS analysis¹ and excluding patients with prior SE or left ventricular dysfunction), see Table 1. It is evident that all subgroups of prior vascular diseases carry a high one-year thromboembolic event rate. Contrasting low risk CHA₂DS₂-VASc (that is, score 0 (male) or 1 (female)) as a reference population vs those with ≥ 1 additional stroke risk factors (ie. CHA₂DS₂-VASc score =1 (male) or =2 (females)) to express the hazard attributable to vascular disease resulted in a crude HR of 2.7 (95%CI 1.7-4.2).

Of note, the event rate for patients with MI was 1.3 per 100 person-years using 5 years of follow-up. To investigate this subgroup of AF patients with a CHADS₂=0 (defined in accordance with the CHA₂DS₂-VASc components (i.e. no prior SE, left ventricular dysfunction, and age<65 years) with prior MI (504 males and 147 females), we excluded those with prior peripheral artery disease and aortic plaque. Contrasting CHA₂DS₂-VASc=0 (male) or 1 (female) as reference population vs CHA₂DS₂-VASc score =1 (male) or =2 (females) resulted in a crude HR of 2.2 (95%CI 1.2-3.8) for one year of follow-up, and for five years of follow-up, HR 1.6 (95%CI 1.0-2.4). Thus, there is still a relative risk increase in ischemic stroke/SE/TIA in the AF group with prior MI compared to those without. Finally, the high stroke risk associated with females with AF has recently been systematically reviewed¹⁴, and this accentuated thromboembolic risk would be further accentuated in the presence of ≥ 1 *additional* stroke risk factors.

Although long follow-up times (i.e. 10 or 12 years) may provide interesting insights into very long-term outcomes in AF patients, caution is warranted as baseline assumptions (on comorbidity and medication use) can be violated; specifically in this context, the requirement of a non-OAC treated cohort with a CHADS₂ score =0. As previously^{1,7}, we have attempted to account for this by censoring person-time if a prescription of an OAC drug was claimed. By design this will censor

some of the studied events, while patients actually treated with OAC will not count in the analysis and thereby introduce an unmeasurable bias. In relation to practical use of risk scoring systems for stratification on treatment decisions, extensive follow-up times seem less interesting.

To conclude, we could perhaps suggest a very simplified risk stratification and thromboprophylaxis algorithm [Figure S1] based on the approach recommended by the ESC and NICE guidelines where the initial step is to identify the low risk patients with $\text{CHA}_2\text{DS}_2\text{-VASc}=0$ (male) or 1 (female), who do not need any antithrombotic therapy [STEP 1]. Subsequently, we should offer effective stroke prevention (which is OAC) to those with ≥ 1 stroke risk factors [STEP 2]. In Step 2, OAC can be with well controlled Vitamin K Antagonist (VKA, with time in therapeutic range $>70\%$) or Non-VKA oral anticoagulant (NOAC), and the decision to anticoagulate is already made, irrespective of $\text{CHA}_2\text{DS}_2\text{-VASc}$ score.

REFERENCES

1. Lip GYH, Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB. Atrial fibrillation patients categorised as “not for anticoagulation” with the 2014 Canadian Cardiovascular Society algorithm are not “low risk.” *Can. J. Cardiol.* 2014. doi:10.1016/j.cjca.2014.10.018.
2. Cairns JA, Healey J, Macle L, Mitchell B, Verma A. The New CCS Algorithm for Antithrombotic Therapy of Atrial Fibrillation is Appropriately Based on Current Epidemiologic Data. *Can. J. Cardiol.* 2014. doi:10.1016/j.cjca.2014.11.021.
3. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. *Can. J. Cardiol.* 2012;28(2):125-36. doi:10.1016/j.cjca.2012.01.021.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;285(22):2864-70.
5. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in “real world” patients with atrial fibrillation treated with dabigatran or warfarin. *Am. J. Med.* 2014;127(4):329-336.e4. doi:10.1016/j.amjmed.2013.12.005.
6. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GYH. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study. *Am. J. Med.* 2014. doi:10.1016/j.amjmed.2014.07.023.
7. Lip GYH, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide co. *Chest* 2014;146(5):1337-46. doi:10.1378/chest.14-0533.
8. Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjøth F, Rasmussen LH, Lip GYH. Intracranial haemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: A nationwide cohort study. *Chest* 2014. doi:10.1378/chest.14-2099.
9. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ* 2011;342:d124. doi:10.1136/bmj.d124.
10. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand. J. Public Health* 2011;39(7 Suppl):26-9. doi:10.1177/1403494811399958.
11. Anandasundaram B, Lane DA, Apostolakis S, Lip GYH. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. *J. Thromb. Haemost.* 2013;11(5):975-87. doi:10.1111/jth.12177.

12. Olesen JB, Lip GYH, Lane DA, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. *Am J Med* 2012;125(8):e12-23. doi:10.1016/j.amjmed.2011.11.024.
13. Rasmussen LH, Larsen TB, Due KM, Tjønneland A, Overvad K, Lip GYH. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. *J. Thromb. Haemost.* 2011;9(7):1301-7. doi:10.1111/j.1538-7836.2011.04308.x.
14. Wagstaff AJ, Overvad TF, Lip GYH, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. *QJM* 2014. doi:10.1093/qjmed/hcu054.

Table 1: Event rates (per 100 person-years) of ischemic stroke/SE/TIA in 980 AF patients with prior vascular disease stratified according to type for 1 and 5 years of follow-up*.

Type of vascular disease	Number of patients	1 year of follow-up		5 years of follow-up	
		Number of events /person-time	Event rate (95% CI)	Number of events /person-time	Event rate (95% CI)
MI	651	12/490	2.5 (1.4-4.3)	23/1,783	1.3 (0.9-1.9)
Peripheral artery disease	294	6/201	3.0 (1.3-6.7)	13/669	1.9 (1.1-3.4)
Both MI and peripheral artery disease	35	3/20	15.0 (4.8-46.4)	5/57	8.7 (3.6-21.0)

*Groups comprising ≤ 5 patients (e.g. aortic plaque and MI) have been omitted from the table (n=7 patients).

Figure S1: A simple practical algorithm for stroke risk stratification and decision making on thromboprophylaxis

